2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Baricitinib vs. Tocilizumab.
Aug 24, 2026DOI: 10.1093/cid/ciaf681Journal ArticleCID
Written by: Nandita NadigAdarsh BhimrajKelly CawcuttKathleen ChiotosAmy L DzierbaArthur Y KimGreg S MartinJeffrey C PearsonAmy Hirsch ShumakerLindsey R BadenRoger BedimoVincent Chi-Chung ChengKara W ChewEric S DaarDavid V GliddenErica J HardySteven JohnsonChristine MacBrayneMari M NakamuraCarlos R OliveiraLaura RileyRobert W ShaferShmuel ShohamPablo TebasPhyllis C TienZachary WillisJoshua WolfJennifer LovelessYngve Falck-YtterRebecca L MorganRajesh T Gandhi
Find these authors on Roon
AK
Dr. Arthur Kim
HIV/AIDS Medicine · MGH
SS
Dr. Shmuel Shoham
Transplant/Immunocompromised States · Johns Hopkins
Summary
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents a new recommendation on the use of baricitinib vs. tocilizumab in hospitalized adults with severe or critical COVID-19. The panel has previously issued recommendations on baricitinib vs. no baricitinib and tocilizumab vs. no tocilizumab, but this new recommendation compares baricitinib to tocilizumab when the decision has been made to give one or the other. The new recommendation does not address combinations of multiple immunomodulatory agents (ie, baricitinib, tocilizumab, abatacept, infliximab). The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach.